Goldman Sachs Alternatives will partner with BC Partners and Synthon’s management to support Synthon’s mission of enabling affordable medicines for patients globally and back the company’s next stage of growth, focused on advancing existing products and launching new medicines by way of leveraging Synthon’s differentiated, science-backed, intellectual property-driven development platform.
Headquartered in the Netherlands, Synthon has approximately 1,600 employees and operates four research laboratories and four manufacturing sites located in the Czech Republic, Spain, Chile, and Argentina. Founded in 1991, Synthon now operates across a diversified base of more than 200 customers across around 100 countries, supplying high-quality complex generic pharmaceuticals based upon its differentiated intellectual property strategy.
The A&O Shearman sponsor side leveraged finance team was led by partner Nick Hallam together with global co-head of private equity Robin Harvey, alongside senior associate Dhruv Mairal and associates Jack Mellett, Ramone Bedi and Nahima Parvin.
